

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 8-K

BIOMARIN PHARMACEUTICAL INC

Form 8-K

April 24, 2002

=====

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 22, 2002

BioMarin Pharmaceutical Inc.  
(Exact name of registrant as specified in its charter)

Delaware	000-26727	68-0397820
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(IRS Employer Identification No.)

371 Bel Marin Keys Boulevard, Suite 210, Novato, California	94949
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: (415) 884-6700

Not Applicable

-----  
(Former name or former address, if changed since last report)  
=====

=====

Item 5. Other Events.

On April 22, 2002, BioMarin Pharmaceutical Inc. (the "Registrant") announced the initiation of a Phase 2 clinical trial of Aryplase (recombinant human N-acetylgalactosamine 4-sulfatase or arylsulfatase B) . The Registrant's press release issued on April 22, 2002 is attached hereto as Exhibit 99.1.

Item 7. Financial Statements, Pro Forma Financial Statements and Exhibits.

(a) Financial Statements of Business Acquired.

Not Applicable.

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 8-K

(b) Pro Forma Financial Information.

Not Applicable.

(c) Exhibits.

Exhibit 99.1      Press Release of the Registrant dated  
April 22, 2002

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BioMarin Pharmaceutical Inc.,  
a Delaware corporation

Date: April 24, 2002

By: /s/ Fredric D. Price

-----  
Fredric D. Price  
Chairman and Chief Executive Officer

EXHIBIT INDEX

Exhibit No.	Description
Exhibit 99.1	Press Release of the Registrant dated April 22, 2002